Ferring To Pioneer Phage Therapies For Crohn’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
The Switzerland-based company targets a novel therapeutic area still small enough for it to make a difference, the development of bacteriophage therapies for disorders thought to be associated with abnormal bacterial microflora, with proof-of-principle studies to begin later this year.